Perspective - (2025) Volume 17, Issue 2
Received: 01-Apr-2025, Manuscript No. jbabm-26-182328;
Editor assigned: 03-Apr-2025, Pre QC No. P-182328;
Reviewed: 17-Apr-2025, QC No. Q-182328;
Revised: 22-Apr-2025, Manuscript No. R-182328;
Published:
29-Apr-2025
, DOI: 10.37421/1948-593X.2025.17.486
Citation: Suzuki, Hanae. ”Microfluidics: Advancing Biomedical Diagnostics and Personalized Medicine.” J Bioanal Biomed 17 (2025):486.
Copyright: © 2025 Suzuki H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Microfluidic platforms have emerged as transformative tools in biomedical diagnostics, offering unparalleled precision in manipulating minute fluid volumes. Their inherent advantages include enabling high-throughput screening capabilities, significantly reducing the consumption of precious reagents, and facilitating the development of point-of-care applications that bring diagnostic power closer to the patient [1].
This miniaturization allows for the creation of exceptionally sensitive and rapid diagnostic assays, adept at detecting subtle biomarkers indicative of various diseases, ranging from infectious agents to various forms of cancer [1].
The integration of these microfluidic systems with sophisticated detection methodologies further amplifies their diagnostic prowess, paving the way for earlier and more accurate disease identification [1].
The convergence of microfluidics with advanced gene editing technologies, such as CRISPR-based systems, presents a particularly potent synergy for the rapid and highly sensitive detection of nucleic acids. This integration allows for the miniaturization of diagnostic workflows, making them suitable for point-of-care settings. Such systems are crucial for identifying pathogens and specific genetic mutations with remarkable speed and specificity, thereby revolutionizing approaches to infectious disease diagnosis and genetic screening [2].
Digital microfluidics, a specialized area leveraging the principles of electrowetting-on-dielectric, provides exceptional control over discrete droplets. This level of control is fundamental for performing complex biochemical assays with minimal sample and reagent volumes. The adaptability of this technology makes it ideal for a wide spectrum of diagnostic applications, including enzyme-linked immunosorbent assays (ELISAs) and nucleic acid amplification tests (NAATs), thereby enabling the development of diagnostic devices that are both miniaturized and highly precise [3].
Microfluidic devices are being ingeniously designed for the isolation and subsequent analysis of circulating tumor cells (CTCs) directly from blood samples. These platforms utilize micro-scale structures to achieve efficient cell capture, often exploiting differences in cell size, deformability, or the presence of specific surface markers. The capability to collect and analyze CTCs non-invasively offers invaluable insights into the progression of cancer and the effectiveness of therapeutic interventions [4].
A primary focus within microfluidics research is the development of lab-on-a-chip devices engineered for rapid point-of-care diagnostics. These integrated systems skillfully combine multiple laboratory functionsâ??sample preparation, chemical reactions, and detectionâ??onto a single, compact chip. This integration facilitates on-site testing for a variety of conditions, including infectious diseases, cardiac markers, and glucose levels, with their portability and user-friendliness being critical for accessibility in remote regions and emergency situations [5].
Significant advancements are being made in the utilization of microfluidic devices to enhance the sensitivity and specificity of immunoassays. By meticulously controlling laminar flow and the mixing dynamics of reagents within these confined channels, these platforms can substantially reduce assay times and improve the detection limits for a diverse range of protein biomarkers. This enhancement is particularly critical for the early diagnosis of diseases where biomarker concentrations may be exceedingly low [6].
The synergy between microfluidics and nanomaterials represents a highly promising strategy for the development of ultrasensitive biosensors. Nanomaterials such as nanoparticles, nanowires, and quantum dots can effectively amplify detection signals and improve the efficiency of capturing target analytes. This potent combination leads to markedly improved detection limits for a broad array of biomolecules that are relevant for disease diagnosis [7].
Microfluidic devices are actively being explored and developed for the rapid detection of viral RNA and DNA, a critical component in the diagnosis of infectious diseases. These platforms are designed to efficiently integrate multiple steps, including sample lysis, nucleic acid extraction, and amplification (such as PCR or isothermal amplification), all within a compact system. This integrated approach facilitates rapid turnaround times for diagnostics, which is especially crucial during disease outbreaks [8].
In the realm of drug discovery and development, microfluidics plays a pivotal role through applications in high-throughput screening of drug candidates and the advancement of personalized medicine. Microfluidic platforms possess the unique ability to simulate intricate in vivo microenvironments, often realized through organ-on-a-chip models. This simulation allows for a more accurate and efficient assessment of drug efficacy and toxicity compared to traditional experimental methods [9].
There is a growing development of microfluidic devices dedicated to multiplexed biomarker detection, enabling the simultaneous measurement of multiple analytes from a single patient sample. This capability is indispensable for the comprehensive diagnosis of complex diseases. It allows for the simultaneous identification of panels of cancer biomarkers or the detailed assessment of immune responses, ultimately leading to more refined and individualized patient profiling [10].
Microfluidic platforms offer substantial benefits for biomedical diagnostics, facilitating high-throughput screening, reducing reagent usage, and enabling point-of-care diagnostics. Their precise fluid manipulation capabilities are crucial for developing sensitive and rapid assays to detect disease biomarkers, including those for infections and cancer. Enhanced diagnostic capabilities result from integration with advanced detection methods [1].
The combination of microfluidics with CRISPR-based gene editing systems provides a powerful approach for rapid and sensitive nucleic acid detection. Miniaturization for point-of-care diagnostics allows for pathogen and genetic mutation identification with high specificity and speed, transforming infectious disease diagnosis and genetic screening [2].
Digital microfluidics, utilizing electrowetting-on-dielectric, offers superior control over discrete droplets, enabling complex biochemical assays with minimal sample and reagent volumes. This technology's adaptability supports various diagnostic applications like ELISAs and NAATs, driving the creation of miniaturized, automated, and highly precise diagnostic devices [3].
Microfluidic devices are designed to isolate and analyze circulating tumor cells (CTCs) from blood. These platforms employ micro-scale structures for efficient cell capture based on size, deformability, or surface markers. Non-invasive CTC collection and analysis yield valuable insights into cancer progression and treatment response [4].
Developing lab-on-a-chip devices for rapid point-of-care diagnostics is a significant area for microfluidics. These integrated systems perform sample preparation, reaction, and detection on a single chip, enabling on-site testing for infectious diseases, cardiac markers, and glucose monitoring. Portability and ease of use are key for remote and emergency settings [5].
Microfluidic devices are enhancing the sensitivity and specificity of immunoassays. By controlling laminar flow and reagent mixing, these platforms can shorten assay times and improve detection limits for protein biomarkers, which is crucial for early diagnosis of diseases with low biomarker concentrations [6].
Integrating microfluidics with nanomaterials is a promising strategy for developing highly sensitive biosensors. Nanoparticles, nanowires, and quantum dots can boost signal amplification and improve analyte capture efficiency, leading to enhanced detection limits for disease-related biomolecules [7].
Microfluidic devices are being developed for rapid detection of viral RNA and DNA, essential for diagnosing infectious diseases. These platforms integrate sample lysis, nucleic acid extraction, and amplification (PCR or isothermal) in a compact system, ensuring quick diagnostic turnaround, especially during outbreaks [8].
Microfluidics is applied in drug discovery and development for high-throughput screening and personalized medicine. Microfluidic platforms can mimic in vivo microenvironments, like organ-on-a-chip models, to assess drug efficacy and toxicity more accurately and efficiently than traditional methods [9].
Microfluidic devices are increasingly designed for multiplexed biomarker detection, allowing simultaneous measurement of multiple analytes from one sample. This is vital for complex disease diagnostics, such as identifying cancer biomarker panels or assessing immune responses, leading to comprehensive patient profiling [10].
Microfluidic technology offers significant advantages in biomedical diagnostics, including high-throughput screening, reduced reagent use, and point-of-care applications. These platforms enable sensitive and rapid detection of disease biomarkers for conditions like cancer and infectious diseases. Integration with technologies like CRISPR and nanomaterials further enhances diagnostic capabilities, allowing for precise nucleic acid detection, improved immunoassay performance, and ultrasensitive biosensing. Digital microfluidics and lab-on-a-chip devices enable complex assays with minimal volumes and facilitate on-site testing. Microfluidics also plays a role in isolating circulating tumor cells, rapid viral detection, and drug discovery through organ-on-a-chip models. Multiplexed detection capabilities allow for simultaneous analysis of multiple biomarkers, leading to more comprehensive disease diagnosis and personalized medicine approaches.
None
None
Journal of Bioanalysis & Biomedicine received 3099 citations as per Google Scholar report
